BMS-275291. Bristol-Myers Squibb.
Bristol-Myers Squibb (BMS) is developing BMS-275291, which is a matrix metalloproteinase (MMP) inhibitor, for the potential treatment of cancer. It was originally developed by Chiroscience R&D (now known as Celltech Group plc), and it inhibits a broad range of MMPs known to be associated with the growth and spread of tumors. Advantageously, it does not inhibit MMP-mediated shedding events, which may be involved in the side effects associated withfirst-generation MMP inhibitors. ByMarch 2001, BMS-275291 was undergoing phase II/III trials, as an adjunct to standard chemotherapy, involving non-small cell lung cancer patients. In March 1999, Lehman Brothers predicted that the compound had a 25% chance of reaching the market, with a possible launch anticipated in 2005 and potential peak sales of $500 million in 2010. In November 2000, Lehman Brothers revised their predictions estimating a 2004 launch with a 20% chance of reaching the market; predicted peak sales were unchanged. In January 2002, Morgan Stanley Dean Witter expressed the view that release of positive phase II/III trials data would surprise stock markets.